Corticosteroid Injection Exhibits Symptomatic Improvement in CTS Patients with Negative EMGs

Brooke G. Garnica
Wayne State University, gu2684@wayne.edu

Aaron R. Prater
Wayne State University

Elizabeth A. Washnock-Schmid
Wayne State University

Alaa Hazime
Henry Ford Health System

Dr. Charles S. Day
Henry Ford Health System

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs
Part of the Musculoskeletal Diseases Commons, and the Orthopedics Commons

Recommended Citation
Garnica, Brooke G.; Prater, Aaron R.; Washnock-Schmid, Elizabeth A.; Hazime, Alaa; and Day, Dr. Charles S., "Corticosteroid Injection Exhibits Symptomatic Improvement in CTS Patients with Negative EMGs" (2022). Medical Student Research Symposium. 140.
https://digitalcommons.wayne.edu/som_srs/140

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.
Corticosteroid Injection Exhibits Symptomatic Improvement in CTS Patients with Negative EMGs

Introduction
While corticosteroid injections for carpal tunnel syndrome (CTS) are effective in patients with mild EMGs, no literature has examined the effectiveness of injections in patients with negative EMGs. We hypothesized that patients with negative EMGs will have minimal symptomatic and functional improvement.

Methods
The Boston Carpal Tunnel Questionnaire (BCTQ) was administered to patients clinically diagnosed with CTS and a negative or mild EMG prior to corticosteroid injection. The BCTQ comprises functional (FSS) and symptom status (SSS) questions. The patient was re-evaluated at 2-weeks, 1-, 3-, and 6-months post-injection. Data were analyzed via one-way ANOVA tests. A post-hoc Benjamini-Hochberg FDR p-value adjustment for multiple comparisons was used to determine significance between time points. Clinically significant improvement was defined as an MCID >0.30. Patients who underwent surgery post-injection were considered to have failed treatment and no longer participated. Analyses were performed using SAS 9.4.

Results
• 33/37 (89.7%) patients (age 50.77±13.20), 15 EMG-mild and 13 EMG-negative participated.
• Corticosteroid injection elicited significant improvement in mean SSS (p=0.0019) and mean FSS (p=0.0118) scores over time from pre-injection to all documented time points for all patients.
• Patients with negative EMG showed improvement between SSS pre-injection and SSS 2-weeks (p=0.0150), and SSS pre-injection and SSS 3-months (p=0.0225). The was not true for patients with mild EMGs.

Conclusion
This data suggest corticosteroid injection for CTS evokes symptomatic and functional improvement for all patients. Negative EMG patients experience symptomatic improvement within the first 2-weeks post-injection and continues for up to 3-months, while mild EMG patients experience no improvement.